Last checked at 18 Jan 2024 07:00
18 January 2024
VALIRX PLC
("ValiRx" or the "Company")
Directorate Change
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces the resignation of Stella Panu as a Non-Executive Director of the Company, effective from 15 April 2024.
Following the fundraise in January 2024, Stella has decided to step down from the Board of ValiRx to concentrate on her other commitments. Stella has agreed to a 3-month handover period to allow sufficient time for the Board to identify an appropriate replacement and ensure a smooth transition of responsibilities.
During Stella's tenure as a Non-Executive Director, she has made significant contributions to the development of the strategy and the changes required to ensure the Company achieves its longer-term growth goals. Stella's expertise and guidance have been invaluable, and the Company would like to express its gratitude for her dedicated service.
With Stella's support, the Company will be working diligently to identify a suitable candidate to fill the vacancy created by her departure. In particular, the Board will be seeking candidates with a background in early-stage pharmaceutical development, aligning with our strategic focus. The Board and management are committed to ensuring a seamless transition and will work closely with Stella to facilitate a comprehensive handover of duties.
Kevin Cox, Chairman of ValiRx commented "I would very much like to extend my sincere appreciation to Stella for her invaluable contributions to ValiRx over the past years. Her knowledge and skills have been instrumental in the successful acquisition of Imagen Therapeutics assets, which have provided a significant milestone in the development of Inaphaea Biolabs. Her presence on the Board and guidance to me will be greatly missed, and I wish her continued success in future endeavours."
The Directors of the Company take responsibility for this announcement.
For more information, please contact:
ValiRx plc
Dr Suzanne Dilly, CEO
| Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
| +44 (0) 115 787 0206 www.vformation.biz
lucy@vformation.biz sue@vformation.biz |
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/Jo Turner/Ludovico Lazzaretti
| Tel: +44 (0) 20 7213 0880 |
Cavendish Capital Markets Limited (Joint Broker)
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate Finance) | Tel: +44 (0) 20 7397 8900 |
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker | Tel: +44 (0) 20 3657 0050
|
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Cautionary statement
Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.